TGFB1I1 and neoplasm: As expected, Hic-5 expression and Src/JNK activity (p-Src and p-JNK) were decreased in the HuCCT1 tumor treated with both 0.5 mg/g and 2.0 mg/g mouse of dasatinib by 80–90% compared with those treated with the vehicle (0.2% DMSO) (vehicle 1 and vehicle 2, respectively) in each of the same mice (Figure 4, left panel).